The biology of the sodium iodide symporter and its potential for targeted gene delivery

M. Hingorani, C. Spitzweg, G. Vassaux, K. Newbold, A. Melcher, H. Pandha, Richard Geoffrey Vile, K. Harrington

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The sodium iodide symporter (NIS) is responsible for thyroidal, salivary, gastric, intestinal and mammary iodide uptake. It was first cloned from the rat in 1996 and shortly thereafter from human and mouse tissue. In the intervening years, we have learned a great deal about the biology of NIS. Detailed knowledge of its genomic structure, transcriptional and post-transcriptional regulation and pharmacological modulation has underpinned the selection of NIS as an exciting approach for targeted gene delivery. A number of in vitro and in vivo studies have demonstrated the potential of using NIS gene therapy as a means of delivering highly conformal radiation doses selectively to tumours. This strategy is particularly attractive because it can be used with both diagnostic (99mTc, 125I, 124I) and therapeutic ( 131I, 186Re, 188Re, 211At) radioisotopes and it lends itself to incorporation with standard treatment modalities, such as radiotherapy or chemoradiotherapy. In this article, we review the biology of NIS and discuss its development for gene therapy.

Original languageEnglish (US)
Pages (from-to)242-267
Number of pages26
JournalCurrent Cancer Drug Targets
Volume10
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Genetic Therapy
Iodides
Chemoradiotherapy
Radioisotopes
Genes
Stomach
Breast
Radiotherapy
Pharmacology
Radiation
Therapeutics
Neoplasms
sodium-iodide symporter
In Vitro Techniques

Keywords

  • Adenovirus
  • Gene therapy
  • Measles virus
  • Radioiodide
  • Radiotherapy
  • Sodium iodide symporter

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Hingorani, M., Spitzweg, C., Vassaux, G., Newbold, K., Melcher, A., Pandha, H., ... Harrington, K. (2010). The biology of the sodium iodide symporter and its potential for targeted gene delivery. Current Cancer Drug Targets, 10(2), 242-267. https://doi.org/10.2174/156800910791054194

The biology of the sodium iodide symporter and its potential for targeted gene delivery. / Hingorani, M.; Spitzweg, C.; Vassaux, G.; Newbold, K.; Melcher, A.; Pandha, H.; Vile, Richard Geoffrey; Harrington, K.

In: Current Cancer Drug Targets, Vol. 10, No. 2, 03.2010, p. 242-267.

Research output: Contribution to journalArticle

Hingorani, M, Spitzweg, C, Vassaux, G, Newbold, K, Melcher, A, Pandha, H, Vile, RG & Harrington, K 2010, 'The biology of the sodium iodide symporter and its potential for targeted gene delivery', Current Cancer Drug Targets, vol. 10, no. 2, pp. 242-267. https://doi.org/10.2174/156800910791054194
Hingorani, M. ; Spitzweg, C. ; Vassaux, G. ; Newbold, K. ; Melcher, A. ; Pandha, H. ; Vile, Richard Geoffrey ; Harrington, K. / The biology of the sodium iodide symporter and its potential for targeted gene delivery. In: Current Cancer Drug Targets. 2010 ; Vol. 10, No. 2. pp. 242-267.
@article{c80c8911e9904853816787a7c34d2446,
title = "The biology of the sodium iodide symporter and its potential for targeted gene delivery",
abstract = "The sodium iodide symporter (NIS) is responsible for thyroidal, salivary, gastric, intestinal and mammary iodide uptake. It was first cloned from the rat in 1996 and shortly thereafter from human and mouse tissue. In the intervening years, we have learned a great deal about the biology of NIS. Detailed knowledge of its genomic structure, transcriptional and post-transcriptional regulation and pharmacological modulation has underpinned the selection of NIS as an exciting approach for targeted gene delivery. A number of in vitro and in vivo studies have demonstrated the potential of using NIS gene therapy as a means of delivering highly conformal radiation doses selectively to tumours. This strategy is particularly attractive because it can be used with both diagnostic (99mTc, 125I, 124I) and therapeutic ( 131I, 186Re, 188Re, 211At) radioisotopes and it lends itself to incorporation with standard treatment modalities, such as radiotherapy or chemoradiotherapy. In this article, we review the biology of NIS and discuss its development for gene therapy.",
keywords = "Adenovirus, Gene therapy, Measles virus, Radioiodide, Radiotherapy, Sodium iodide symporter",
author = "M. Hingorani and C. Spitzweg and G. Vassaux and K. Newbold and A. Melcher and H. Pandha and Vile, {Richard Geoffrey} and K. Harrington",
year = "2010",
month = "3",
doi = "10.2174/156800910791054194",
language = "English (US)",
volume = "10",
pages = "242--267",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - The biology of the sodium iodide symporter and its potential for targeted gene delivery

AU - Hingorani, M.

AU - Spitzweg, C.

AU - Vassaux, G.

AU - Newbold, K.

AU - Melcher, A.

AU - Pandha, H.

AU - Vile, Richard Geoffrey

AU - Harrington, K.

PY - 2010/3

Y1 - 2010/3

N2 - The sodium iodide symporter (NIS) is responsible for thyroidal, salivary, gastric, intestinal and mammary iodide uptake. It was first cloned from the rat in 1996 and shortly thereafter from human and mouse tissue. In the intervening years, we have learned a great deal about the biology of NIS. Detailed knowledge of its genomic structure, transcriptional and post-transcriptional regulation and pharmacological modulation has underpinned the selection of NIS as an exciting approach for targeted gene delivery. A number of in vitro and in vivo studies have demonstrated the potential of using NIS gene therapy as a means of delivering highly conformal radiation doses selectively to tumours. This strategy is particularly attractive because it can be used with both diagnostic (99mTc, 125I, 124I) and therapeutic ( 131I, 186Re, 188Re, 211At) radioisotopes and it lends itself to incorporation with standard treatment modalities, such as radiotherapy or chemoradiotherapy. In this article, we review the biology of NIS and discuss its development for gene therapy.

AB - The sodium iodide symporter (NIS) is responsible for thyroidal, salivary, gastric, intestinal and mammary iodide uptake. It was first cloned from the rat in 1996 and shortly thereafter from human and mouse tissue. In the intervening years, we have learned a great deal about the biology of NIS. Detailed knowledge of its genomic structure, transcriptional and post-transcriptional regulation and pharmacological modulation has underpinned the selection of NIS as an exciting approach for targeted gene delivery. A number of in vitro and in vivo studies have demonstrated the potential of using NIS gene therapy as a means of delivering highly conformal radiation doses selectively to tumours. This strategy is particularly attractive because it can be used with both diagnostic (99mTc, 125I, 124I) and therapeutic ( 131I, 186Re, 188Re, 211At) radioisotopes and it lends itself to incorporation with standard treatment modalities, such as radiotherapy or chemoradiotherapy. In this article, we review the biology of NIS and discuss its development for gene therapy.

KW - Adenovirus

KW - Gene therapy

KW - Measles virus

KW - Radioiodide

KW - Radiotherapy

KW - Sodium iodide symporter

UR - http://www.scopus.com/inward/record.url?scp=77950687906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950687906&partnerID=8YFLogxK

U2 - 10.2174/156800910791054194

DO - 10.2174/156800910791054194

M3 - Article

C2 - 20201784

AN - SCOPUS:77950687906

VL - 10

SP - 242

EP - 267

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 2

ER -